Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined with Lenvatinib vs Sequential Lenvatinib for Intermediate/Advanced HCC
NCT05220020Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05220020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220020.